
US pharmaceutical companies are increasingly licensing high-quality drug assets from China to replenish pipelines amid a looming patent cliff. This strategic shift, involving billions in deal value...
More >US pharmaceutical companies are increasingly licensing high-quality drug assets from China to replenish pipelines amid a looming patent cliff. This strategic shift, involving billions in deal value...
More >